623 related articles for article (PubMed ID: 26350096)
1. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Fang B
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):27-38. PubMed ID: 26350096
[TBL] [Abstract][Full Text] [Related]
2. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
Lv J; Wang J; Chang S; Liu M; Pang X
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):17-26. PubMed ID: 26487443
[TBL] [Abstract][Full Text] [Related]
3. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
[TBL] [Abstract][Full Text] [Related]
4. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.
Chen Z; Cheng K; Walton Z; Wang Y; Ebi H; Shimamura T; Liu Y; Tupper T; Ouyang J; Li J; Gao P; Woo MS; Xu C; Yanagita M; Altabef A; Wang S; Lee C; Nakada Y; Peña CG; Sun Y; Franchetti Y; Yao C; Saur A; Cameron MD; Nishino M; Hayes DN; Wilkerson MD; Roberts PJ; Lee CB; Bardeesy N; Butaney M; Chirieac LR; Costa DB; Jackman D; Sharpless NE; Castrillon DH; Demetri GD; Jänne PA; Pandolfi PP; Cantley LC; Kung AL; Engelman JA; Wong KK
Nature; 2012 Mar; 483(7391):613-7. PubMed ID: 22425996
[TBL] [Abstract][Full Text] [Related]
5. Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.
Drosten M; Barbacid M
J Mol Med (Berl); 2016 Feb; 94(2):121-35. PubMed ID: 26526121
[TBL] [Abstract][Full Text] [Related]
6.
Chung WJ; Daemen A; Cheng JH; Long JE; Cooper JE; Wang BE; Tran C; Singh M; Gnad F; Modrusan Z; Foreman O; Junttila MR
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):E10947-E10955. PubMed ID: 29203670
[No Abstract] [Full Text] [Related]
7. Challenges in Ras therapeutics in pancreatic cancer.
Choi M; Bien H; Mofunanya A; Powers S
Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
[TBL] [Abstract][Full Text] [Related]
8. mTORC1 upregulation via ERK-dependent gene expression change confers intrinsic resistance to MEK inhibitors in oncogenic KRas-mutant cancer cells.
Komatsu N; Fujita Y; Matsuda M; Aoki K
Oncogene; 2015 Nov; 34(45):5607-16. PubMed ID: 25703330
[TBL] [Abstract][Full Text] [Related]
9. ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer.
Aytes A; Mitrofanova A; Kinkade CW; Lefebvre C; Lei M; Phelan V; LeKaye HC; Koutcher JA; Cardiff RD; Califano A; Shen MM; Abate-Shen C
Proc Natl Acad Sci U S A; 2013 Sep; 110(37):E3506-15. PubMed ID: 23918374
[TBL] [Abstract][Full Text] [Related]
10. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
11. Mutations in PIK3CA are infrequent in neuroblastoma.
Dam V; Morgan BT; Mazanek P; Hogarty MD
BMC Cancer; 2006 Jul; 6():177. PubMed ID: 16822308
[TBL] [Abstract][Full Text] [Related]
12. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
13. LSL-KrasG12D; LSL-Trp53R172H/+; Ink4flox/+; Ptf1/p48-Cre mice are an applicable model for locally invasive and metastatic pancreatic cancer.
Ma L; Saiyin H
PLoS One; 2017; 12(5):e0176844. PubMed ID: 28475592
[TBL] [Abstract][Full Text] [Related]
14. KRAS-related proteins in pancreatic cancer.
Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
[TBL] [Abstract][Full Text] [Related]
15. Identification of subsets of actionable genetic alterations in KRAS-mutant lung cancers using association rule mining.
Tayou J
Cell Oncol (Dordr); 2018 Aug; 41(4):395-408. PubMed ID: 29679238
[TBL] [Abstract][Full Text] [Related]
16. Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer.
Jin L; Jin MH; Nam AR; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Lett; 2017 Dec; 411():162-170. PubMed ID: 29024814
[TBL] [Abstract][Full Text] [Related]
17. ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.
Hu L; Liang S; Chen H; Lv T; Wu J; Chen D; Wu M; Sun S; Zhang H; You H; Ji H; Zhang Y; Bergholz J; Xiao ZJ
Proc Natl Acad Sci U S A; 2017 May; 114(20):E3964-E3973. PubMed ID: 28468801
[TBL] [Abstract][Full Text] [Related]
18. Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.
Roskoski R
Pharmacol Res; 2021 Oct; 172():105806. PubMed ID: 34450320
[TBL] [Abstract][Full Text] [Related]
19. K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives.
Asati V; Mahapatra DK; Bharti SK
Eur J Med Chem; 2017 Jan; 125():299-314. PubMed ID: 27688185
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]